Caspofungin for the treatment of azole resistant candidemia in a premature infant

Journal of Perinatology

Volumn 27, Issue 2, 2007, Pages 127-129

  Smith, P B ^a,b   Steinbach, W J ^a   Cotten, C M ^a   Schell, W A ^a   Perfect, J R ^a   Walsh, T J ^c   Benjamin Jr , D K ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; CALCIUM; CASPOFUNGIN; FLUCONAZOLE; GENTAMICIN; MAGNESIUM; METRONIDAZOLE; NYSTATIN; PHOSPHORUS; PYRROLE; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CULTURE; BRAIN HEMORRHAGE; CANDIDA ALBICANS; CANDIDEMIA; CASE REPORT; CESAREAN SECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; KIDNEY DISEASE; LOADING DRUG DOSE; MAGNESIUM BLOOD LEVEL; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROSTOMY; NEWBORN; NEWBORN INFECTION; NONHUMAN; PARENTERAL NUTRITION; PATENT DUCTUS ARTERIOSUS; PHOSPHATE BLOOD LEVEL; PNEUMOTHORAX; PREMATURITY; RENOGRAPHY; REPEATED DRUG DOSE; SIDE EFFECT; SMALL INTESTINE PERFORATION; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT RESPONSE; URINE CULTURE;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; HUMANS; HYPERCALCEMIA; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 33846662105     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211637     Document Type: Article

References (8)

1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA et al. Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110: 285-291.
2. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22: 747-749.
3. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-4545.
4. Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093-1097.
5. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25: 770-777.
6. Kantarjian HM, Saad MF, Estey EH, Sellin RV, Samaan NA. Hypercalcemia in disseminated candidiasis. Am J Med, 1983; 74: 721-724.
7. Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000; 46: 338-340.
8. Pfaller MA, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC et al. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A2National Committee for Clinical Laboratory Standards. National Committee for Clinical Laboratory Standards: Wayne, Pennsylvania, 2002.